SRGN and breast carcinoma: The potential role of serglycin in metastatic dissemination has been investigated in a mouse model of breast cancer, where knockout of serglycin resulted in CTCs unable to establish metastatic tumors although not affecting primary tumor formation (Roy et al., 2016).